Overview

To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females

Status:
Completed

Trial end date:
2005-10-01

Target enrollment:

Participant gender:

Summary

The study aimed to compare age and gender differences for increasing doses of mirabegron when given to healthy young and elderly males and healthy young and elderly females.

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Mirabegron